Autologous chondrocytes

Autologous chondrocytes are the specialized cells of the articular cartilage responsible for the synthesis and maintenance of the extracellular matrix, primarily composed of type II collagen and proteoglycans (StatPearls, 2023). In clinical applications, these cells are harvested from a patient's own healthy, non-weight-bearing cartilage, expanded in vitro, and re-implanted into chondral defects to facilitate tissue regeneration (FDA, 2016). This therapeutic approach, known as Autologous Chondrocyte Implantation (ACI), aims to restore the functional and structural integrity of the joint surface, thereby preventing the progression to osteoarthritis (PubMed, PMC6669432). Unlike traditional pharmacological targets such as receptors or enzymes, autologous chondrocytes serve as the active therapeutic agent in a cell-based regenerative medicine strategy (NIH, 2021). Commercial products like MACI (Matrix-induced autologous chondrocyte implantation) utilize these cells seeded on a porcine collagen membrane to improve surgical handling and cell distribution (Vericel, 2023). The primary mechanism involves the cells' ability to integrate with host tissue and produce a hyaline-like matrix that mimics the mechanical properties of native cartilage (Journal of Orthopaedic Research, 2019).

Other names

Autologous cartilage cellsCultured autologous chondrocytesACI cells

Regeneration of articular cartilage through the implantation of expanded autologous cells that integrate into the defect and produce a hyaline-like extracellular matrix.